News

Home / News and Events

November 08, 2022 | Featured

Intract Announces Publication on Pre-clinical Data with Merck & Co. on Colon Targeted Delivery of JAK Inhibitor using Phloral® Technology

September 16, 2022 | Featured

Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies

April 01, 2022 | Featured

Intract Pharma Appoints Dr Vipul Yadav as Chief Executive Officer

September 27, 2021 | Featured

Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines

April 22, 2021 | Featured

Intract Pharma and NIBEC Enter into an Agreement to Develop a Novel Oral Peptide Therapy for Treatment of Ulcerative Colitis.

April 01, 2021 | Featured

Intract Pharma Enters into Research Collaboration with Ferring Pharmaceuticals to Evaluate Oral delivery of Monoclonal Antibodies for Treatment of Chronic Gastrointestinal Diseases

August 20, 2020 | Featured

Intract Pharma Limited and Celltrion Group announce collaboration for development of oral Infliximab.

May 26, 2020 | Featured

Intract Pharma and N&S Pharmacy Investment announce partnership to develop orally-delivered GLP-1R agonist peptide therapeutic

May 05, 2020 | Featured

Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics

Page: 1 2 3 >

Copyright © 2018 Intract Pharma

A site by: Web Design London